• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Biosynth Carbosynth

    Qosina

    Quotient Sciences

    IDT Biologika

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Biosynth Carbosynth

    Qosina

    Quotient Sciences

    IDT Biologika

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Pandemic’s Become an Insurmountable Opportunity

    Every Cloud has a Silver Lining(?)

    The Pandemic’s Become an Insurmountable Opportunity
    Related CONTENT
    • Bora Pharmaceuticals
    • Aenova
    • W. R. Grace FCMS
    • WuXi AppTec
    • PCI Pharma Services
    Emil W. Ciurczak, Contributing Editor10.14.20
    It was very sad. So many small businessmen, working hard, learning their trade, and contributing to the greater good, were put out of business. No, not what you are thinking, I am referring to the blacksmiths, horse ranchers, breeders, and carriage makers who were put out of business by Henry Ford and his ilk. Or, what about all those cobblers, seamstresses, potters, and such, all displaced by factories during the Industrial Revolution? Type used to be set by hand at newspapers, all those folks lost their jobs. Toll-takers? Telephone operators? Are you starting to see my point? In no way am I ignoring the pain and loss of the moment, just showing it is not unique in history—the 1917-1920 “Spanish” flu killed millions, malaria in developing nations, and measles in Hawaii soon after being visited by Europeans.

    Just as a stray asteroid or comet sped up evolution of the mammals by eliminating the dinosaurs, this heart-breaking virus has sped up a lot of things that were already happening. People were already purchasing more and more on-line and “brick and mortar” stores were already closing. People were already beginning to eschew movie theaters for streaming movies, order from delivery service, in lieu of dining out, and so forth. The shut-down has merely speeded things up.

    As I mentioned in recent columns, the 12,000-mile supply chain of the Pharma industry was about to go the way of hand-picking cotton when faced by the cotton-gin. And, I believe it will improve the quality and availability of the products we make. Anyone who watched TV during the pandemic has seen some innovative methods of producing an appearance of “togetherness.” We had a virtual celebration of graduating students, late night shows combined images and the sounds of individual musicians to (somewhat) generate the sound of an orchestra/band, and many religious services are held via Zoom or Skype. Can this connectivity be expanded to Pharma?

    When I attended the Contract Pharma conference last September, my knowledge of how contract manufacturing organizations (CMOs) work was greatly increased. Having spent the bulk of my career with larger Pharma companies (both as employee and consultant), I hadn’t known how complex the CMO business really was. Several product delivery designs particularly struck me: the final product was based on the efforts of numerous suppliers. While not as complex as the automotive industry, it was hardly an in-house operation. Logically, this is the result of major companies outsourcing one function after another. The distribution, one performed by the producer, was outsourced to distribution centers, each handling numerous companies’ products.

    Packaging, now far more complex than “just” bottles, includes all types of dispensers, blister packages, and even such additions as “child-resistant” caps and desiccant inserts require more hardware than the big companies wish to acquire, especially when they produce at so many locations. It goes without saying that labels and containers have always been produced by third-party vendors, but now, as the delivery systems get more imaginative, more and more vendors become involved.

    So, now we have the “perfect storm” of supply chains: dozens of sites domestic and overseas, producing dozens of products, supplied by dozens of independent vendors all spread over thousands of miles. That means all the parts of the puzzle—raw materials, excipients, labels, desiccants, bottles/blisters/dispensers, and distribution of the product—not to mention analysis and stability testing are, by definition, dependent upon frequent and easy (mostly air) transport of goods and personnel (mostly QA and formulators) to and between sites.

    Now, like a huge game of Jenga, COVID-19 pulled out one too many blocks, resulting in the current state of affairs. There are a number of shortages of various products in pharmacies, but, more to the point, it is almost impossible for Quality inspectors to visit their contract manufacturers, thus, the “honor system” may need to suffice. Although, if all manufacturers could be trusted, QA departments and the FDA/EMA inspectors wouldn’t exist, would they?

    However, a number of notable things have come along in recent years while not seemingly related, but may meld into a “new way” of pharmaceutical manufacturing. These are:

    1. Lifecycle Management. This push by the U.S. FDA was meant to encourage Pharma manufacturers to continually improve their products as they gain experience manufacturing them, over time. Under batch-style cGMP manufacturing, this is difficult, at best, unless just being more careful making the product is considered “better.”

    2. Continuous Manufacturing (CM). This approach, or even merely using QbD, allows a company to change its process (legally) and make continuous improvements. In the time of less employees on site and still a need for drug products, CM needs less hands-on (smaller numbers of operators), less space, less HVAC, etc., while making the product better and giving the ability for older products to be made more efficiently and with a lower cost of goods sold (COGS).

    3. Pricing Legislation. Many Western countries have stringent pricing restrictions already in place and President Trump recently signed an executive order, stating that Medicare needs to be given the same prices that large multi-nationals give countries with a national health service as well as other restrictions. If Pharma companies do not reduce the costs of manufacturing, their profits will quickly evaporate. Continuous manufacturing is one of the best ways to reduce COGS. It reduces waste as well as reduces power and time demands. The quality of continuous monitoring also ensures that recalls are essentially eliminated, as well, further lowering the COGS.

    4. Shrinking Footprints of the Giants. I’ll merely point out that the largest Pharma companies are divesting many of their sites, making them more dependent upon contract operations.

    5. Pipeline Interruptions. In the simplest of terms, cost isn’t everything. While buying an item from 5,000 miles away can save 5%, how much does it cost when it isn’t delivered for a month? Therefore, using Occam’s razor, it is simpler to buy “local” than try to save a few shillings on long-distance purchases. “But,” you may say, “the local material isn’t exactly the same.” True, but, as we keep stating, with QbD, legal changes may be made in the production to ensure consistent final product quality.

    Putting all these together, we have a potential for a new paradigm in producing pharmaceutical products.

    1. With the assistance and guidance of their sponsors, contract manufacturers can be given the fruits of years of QbD investigations. Indeed, CMOs can use the models generated at the “mother-ship” for their local production, using locally obtained raw materials.

    Proprietary companies can even share formulation details (under NDAs, of course) and even “lend” or sell or lease the production equipment currently used for the production of the final dosage forms, especially after patent protection ends. That would help off-set the expected loss of sales to generic competition. It allows the big boys to make back some capital investment costs and assures a better product for the public.

    2. In light of the cost of product issues (restraints by governmental agencies), it would be a neat idea for some deeper partnerships (of course, while observing all anti-trust, anti-competition laws) between proprietary companies and generics/contract companies.

    Assuming that the initiator companies have moved to QbD and, hopefully, CM, this would allow transfer of the production to the secondary site a simpler task. In fact, since patent protection will end for any branded product, no matter what mechanisms are utilized, maybe it would be better to accelerate the “end of the road.”

    By that, I mean enter into “relationships” with contract manufacturers or generic houses to produce the products years before the patent ends. The generic/CMO could supply the initiator with the drug, branded as it had been, but learning how to produce it at the same quality as the initiator. In fact, if it is being produced by CM, the bigger company can actually supply the hardware and teach the new company how to best use it. For example, Pfizer has been putting CM set-ups into trailers and shipping them to the locations where it wasn’t developed, assuring fast start-up times for existing products at new locations.

    This program could be financed in several manners—I leave it up to the money-people to iron out details:

    1. The initiator company can supply or underwrite the CM equipment for the smaller site. Payment could be over years or in the form of portions of the profits that the CMO or generic makes after patent expiry. So, in effect, the second company would make the products for the initiator company, make a profit, and learn how to make future products by CM, increasing quality and meeting pricing laws.

    2. Any cooperative deal might even include the chosen (smaller) company paying a fee to the initiator company for a set period of time to repay getting a (much longer) head-start on any other generic competitors. All contracts must be within legal constraints, of course.

    If this approach works, the larger, initiator companies could become, in reality, the R&D centers, formulators of new products including stability work, and the designers of the final dosage form. After product-introduction and gaining an idea of the level of sales potential for each product, the production can be transferred with proper validation, of course, to the secondary, contract or generic sites.

    This approach would allow the major sites to continue R&D and formulation with fewer personnel and a smaller footprint. In fact, the sites they are downsizing could be sold to or converted into contract sites for the bulk of production.

    I see this trend in some places already. I just think the post-pandemic world can be made to adapt to this new (and to some) radical paradigm. Thoughts?


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Suggested For You
    Bora Pharmaceuticals Bora Pharmaceuticals
    Aenova Aenova
    W. R. Grace FCMS W. R. Grace FCMS
    WuXi AppTec WuXi AppTec
    PCI Pharma Services PCI Pharma Services
    Sekisui Sekisui
    pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    Clean Cells Expands Bioproduction Capabilities Clean Cells Expands Bioproduction Capabilities
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Lakes BioScience Signs Agreement with Cytvia Lakes BioScience Signs Agreement with Cytvia
    Boyds Opens US Office in PA Boyds Opens US Office in PA
    GeneQuine, Exothera Enter Gene Therapy Partnership GeneQuine, Exothera Enter Gene Therapy Partnership
    Repligen and Navigo Launch Antibody Technology Platform Repligen and Navigo Launch Antibody Technology Platform

    Related Content

    • Bora Pharmaceuticals

      Bora Pharmaceuticals

      ...
      Lonnie Barish, VP, Business Development 03.09.22

    • Aenova

      Aenova

      ...
      Susanne Knabe, Head of Communication & PR 11.30.21

    • W. R. Grace FCMS

      W. R. Grace FCMS

      ...
      Stella Ip, Director Marketing Health and Life Sciences 11.23.21


    • WuXi AppTec

      ...
      Daja Herald, Marketing Director 11.22.21

    • Drug Development
      PCI Pharma Services

      PCI Pharma Services

      ...
      Jessica Kloster, Marketing Manager 10.20.21

      Trending
      • Royalty Pharma and Jefferies Invest $111M in ApiJect
      • Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
      • Piramal Pharma Solutions New API Plant In Canada Now Online | Contract Pharma
      • Biopharma Manufacturing Facility Construction | Contract Pharma
      • Next-Gen Lab Services | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login